Angelini Pharma, founded in 2008, operates at the intersection of the Manufacturing and Pharmaceutical industries, with headquarters in Italy. Their guiding mission, "Our passion for science leads us every day to care for people's health," is evident in their focus on developing innovative treatments for CNS and mental health disorders, alongside a strong presence in the consumer health segment.
The company is driven by a clear vision to transform into a leading European pharma entity. This is achieved through a robust growth pipeline, strong collaborations with top-tier research institutes, and dynamic partnerships with strategic allies. The recent €1.50M grant investment from the European Commission on 01 July 2023 underscores the external confidence in Angelini Pharma's potential to deliver innovative health solutions.
As part of Angelini Industries, the company offers a stable yet dynamic investment opportunity, with a strong commitment to advancing health outcomes and enhancing quality of life for patients and their families.